Daewoong CO.,LTD.
Daewoong Pharmaceutical is consolidating its global competitiveness and R&D capabilities.
Daewoong Pharmaceutical believes that the growth of employees translates into the growth of the company.
Daewoong Pharmaceutical will leap beyond Korea and into the world.
Daewoong Pharmaceutical believes that the growth of employees translates into the growth of the company.
Daewoong Pharmaceutical will leap beyond Korea and into the world.
Product Information
Satellite Symposium
Polypill or SPC Therapy for Multiple Risk Patients
Organized by CVRF and Supported by Educational Grant from Daewoong CO.,LTD.
Thursday, April 22
12:10 PM ~ 12:51 PM * Korea Standard Time (UTC/GMT +9:00)
Live Theater (Channel 2)
Moderator(s): Myeong-Ki Hong
| 12:10 PM | Opening Remarks Speaker: Myeong-Ki Hong |
| 12:15 PM | Double Prevention of CVD Risk for Hypertensive Patients by Polypill  Lecturer: Jin-Man Cho |
| 12:30 PM | Lower Is Better & Combination Is Better Lecturer: Soe-Hee Ann |
| 12:45 PM | Discussion with Q & A |
New Treatment Strategy for Atherosclerosis in High Risk Patients
Organized by CVRF and Supported by Educational Grant from Daewoong CO.,LTD.
Friday, April 23
3:50 PM ~ 4:50 PM * Korea Standard Time (UTC/GMT +9:00)
Live Theater (Channel 2)
Moderator(s): Donghoon Choi
Panelist(s): Hyungdon Kook, Jun-Bean Park
| 3:50 PM | Opening Remarks Speaker: Donghoon Choi |
| 3:55 PM | What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia? Lecturer: Duk-Woo Park |
| 4:15 PM | Earlier Is Better & Combination Is Better Lecturer: Hwan-Cheol Park |
| 4:35 PM | Discussion with Q & A |